US/UK/Canada

Share

Contacts

  • Roland Frösing

    Acting CEO


    +46 723 20 61 00
  • Torbjörn Sannerstedt

    Acting CFO


    +46 708 66 22 55

    • Links

    Quotes

    The fact that ChloraSolv, with very good efficacy, now can be used on venous leg ulcers and diabetic foot ulcers is very positive, not only for the patients and relatives but also for healthcare and society as this patient group is connected with large healthcare costs.
    Karin Fischer, CEO, RLS Global
    We are pleased to receive a positive confirmation from Lloyd’s register that ChloraSolv satisfies all required technological requirements.
    Karin Fischer, CEO of RLS Global
    RLS now has a detailed plan with activities for bringing ChloraSolv to the European markets in a structured manner.
    Karin Fischer, CEO
    Pick a time period -
    Tags ( Active)

    ChloraSolv is available in the UK through NHS Supply Chain

    As of 11[th] of July 2022, ChloraSolv is available in the UK to NHS (National Health Service) organizations who purchase from NHS Supply Chain or directly from ConvaTec. ChloraSolv is available to all NHS facilities who have an account at NHS Supply Chain. It is applicable to a range of settings, including hospitals as well as primary and home care settings. ChloraSolv also can be purchased directly from ConvaTec, RLS' exclusive distribution partner for ChloraSolv in Europe.ChloraSolv’s inclusion on the NHS Supply Chain advanced wound care framework is the first step to enabling access to

    Further progress with ChloraSolv[®] roll out across Europe – market access activities in the Netherlands signal positive momentum

    RLS Global, a medical healthcare company based in Sweden, and ConvaTec, one of the world’s leading advanced wound care companies, have made continued progress with the distribution and commercialisation of ChloraSolv[®], a ground-breaking gentle wound debrider, in Europe.After intensive market preparation and work with specialist wound experts in the Netherlands, ChloraSolv[®] gel was listed on January 1, 2022 in the Z- index and received a positive recommendation for reimbursement from Zorginstituut Nederland (ZN). Chlorasolv[®] is already available in other European markets such as the

    RLS Global clinical study, ChloraSolv01, published in the Journal of Wound Care

    RLS Global is pleased to announce that the outcome of the completed clinical study ChloraSolv01 is published today in the Journal of Wound Care Vol 30, No 6, June 2021. Data from this clinical study show that a treatment regimen based on ChloraSolv could represent a valuable treatment option for patients suffering from hard-to-heal wounds.The wounds that were treated in the ChloraSolv01 clinical study were hard-to-heal, lower extremity ulcers which had more than 50% coverage of devitalized tissue. Using ChloraSolv once a week for 5 weeks resulted in a 73% reduction of the devitalized tissue

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe